RAS Interaction with PI3K: More Than Just Another Effector Pathway.

By E. Castellano, Julian Downward. Genes & cancer, 2011

736 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/2e6d22e351b99c566dba9825ec0114150bd351fe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Jason Moffat
2. Gautam Sethi
3. Frederick P. Roth
4. D. Durocher
5. S. Angers
6. C. Der
7. D. Fruman
8. P. Dirks

In Oncology

1. S. Angers
2. C. Der
3. P. Dirks
4. Z. Steinhart

Citations in the corpus

• KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, background): “PIP3 can then activate amultitude of proteins that include RACGEFs, PDK1, and the AKT1/2/3 serine– threonine kinases.”
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “Subsequently, PI3K catalytic subunit p110 can form a complete active PI3K enzyme [53] (Fig.”
• High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. (2015, positive): “We observe multiple hits downstream of the driver mutations in all three MAPK pathway mutants (Figure 4B), including selective PI3K dependency in the KRAS mutant background, consistent with KRAS activation of the PI3K/AKT pathway (Boj et al., 2015; Castellano and Downward , 2011).”